Sensible Biotechnologies
Cell-based mRNA design and manufacturing platform
CORE INFO
Sensible Biotechnologies provides pharma and biotech companies with tools to design, produce, and support development of therapeutic mRNA inside engineered living cells. Its platform combines sequence design, producer cell lines, extraction, purification, and manufacturing support as an alternative to conventional cell-free transcription.
- Series A financing totaled $27 million in equity, with up to $20 million in non-dilutive funding included in a $47 million package announced October 6, 2026; Oxford Science Enterprises was identified as the lead by transaction sources.dlapiper.com
- Letters of intent: 10 biotech companies and research groups had expressed interest in testing Sensible's mRNA, according to the company's profile.ycombinator.com
- Axios reported that the latest financing separated a $27 million equity raise from additional non-dilutive funding, while naming OTB Ventures and In-Q-Tel as leads in its coverage.axios.com
WHY WE WOULD WORK AT SENSIBLE BIOTECHNOLOGIES
Advance Better Medicines
Help unlock the next generation of mRNA therapeutics through a platform designed to make RNA safer, more effective, and easier to manufacture.
Build Breakthrough Technology
Work on VECTOR™, combining AI-assisted sequence design, engineered producer cells, and cell-based manufacturing for linear, circular, and self-amplifying RNA.
Turn Biology Into Scale
Contribute to PromPT™, Sensible's technology for selectively capturing target mRNA inside cells, and help advance the platform toward clinical-grade production.
Collaborate With Industry Leaders
Work alongside partners including Sartorius Stedim Biotech, Ginkgo Bioworks, and NVIDIA on manufacturing, synthetic biology, and computational mRNA design.
Join a Global Team
Collaborate across Oxford, Bratislava, Šarišské Michalany, and the United States in an international environment spanning AI, RNA biology, and bioprocess engineering.
Grow With Real Momentum
Join an approximately 55-person company backed by a $27 million Series A and up to $20 million in non-dilutive funding as it expands toward clinical and commercial manufacturing.
MARKET AND TRACTION
GROWTH TACTICS
NOTABLE CUSTOMERS
KEY METRICS
✦ KEY METRICCOMPETITIVE ADVANTAGE
MARKET POSITION
PRODUCT AND TECH
VECTOR™ Platform
An integrated platform for AI-assisted mRNA sequence design, engineered producer cell lines, cell-based production, and scale-up. It supports linear, circular, and self-amplifying RNA modalities.
AI mRNA Design
Computational tools generate, optimize, and screen large numbers of mRNA sequence candidates, including RNA folding and packaging analysis. The approach is intended to improve sequence performance and accelerate therapeutic development.
Engineered Cell Production
Proprietary living producer cell lines manufacture therapeutic mRNA inside cells rather than through conventional cell-free transcription. This approach is designed to produce naturally modified mRNA with fewer impurities and lower immunogenicity.
PromPT™ Extraction
A patented Programmable mRNA Protein Transporter technology designed to selectively capture target mRNA inside cells for extraction and purification. It addresses the downstream recovery of cell-produced RNA.
Manufacturing Support
Process development, scale-up, analytical development, quality control, and cGMP manufacturing support for partner and internal mRNA programs. Sensible also offers licensing of proprietary sequences and producer strains, alongside co-development partnerships.